# Radiation Therapy and Stereotactic Radiosurgery With or Without Temozolomide or Erlotinib in Treating Patients With Brain Metastases Secondary to Non-Small Cell Lung Cancer

> **NCT00096265** · PHASE3 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 126 (actual)

## Conditions studied

- Metastatic Malignant Neoplasm in the Brain
- Recurrent Non-Small Cell Lung Carcinoma
- Stage IV Non-Small Cell Lung Cancer AJCC v7

## Interventions

- **RADIATION:** 3-Dimensional Conformal Radiation Therapy
- **DRUG:** Erlotinib Hydrochloride
- **RADIATION:** Stereotactic Radiosurgery
- **DRUG:** Temozolomide

## Key facts

- **NCT ID:** NCT00096265
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-10-06
- **Primary completion:** 2011-06-14
- **Final completion:** 2012-04-01
- **Target enrollment:** 126 (ACTUAL)
- **Last updated:** 2018-03-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00096265

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00096265, "Radiation Therapy and Stereotactic Radiosurgery With or Without Temozolomide or Erlotinib in Treating Patients With Brain Metastases Secondary to Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00096265. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*